Depersonalization disorder: pharmacological approaches
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Depersonalization disorder (DPD) is a chronic and distressing condition with a prevalence in the general population between 0.8 and 2%. Several neurobiological studies in the last decade have shown that patients have suppressed limbic activation to emotional stimuli. Such findings are in line with a model which suggests that the condition is generated by an anxiety-triggered, 'hard-wired' inhibitory response to threat. Such a mechanism would ensure the preservation of adaptive behavior, during situations normally associated with overwhelming and potentially disorganizing anxiety. In DPD, such a response would become chronic and dysfunctional. Depersonalization remains a condition for which no definitive treatment exists, and for which conventional medications, such as antidepressants or antipsychotics, have been found to be of little value. Fortunately, a few promising lines of pharmacological treatment have emerged in recent years, although more rigorous studies are needed. For example, a number of studies suggest that opioid receptor antagonists such as naltrexone and naloxone are useful in at least a subgroup of patients. In spite of initial expectations, the use of lamotrigine as a sole medication has not been found useful. However, open-label trials suggest that its use as an add-on treatment with selective serotonin reuptake inhibitors (SSRIs) is beneficial in a substantial number of patients. Similarly, the use of clonazepam, particularly in conjunction with SSRI antidepressants, appears to be beneficial in patients with high levels of background anxiety. In line with the stress-related model of depersonalization, those neurotransmitter systems of relevance to depersonalization are known to play important inhibitory roles in the regulation of the stress response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
Psychotomimesis Mediated by κ Opiate Receptors
Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986) · Science · doi:10.1126/science.3016896 · Cited by 857
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426
Depersonalization: neurobiological perspectives.
Sierra, M., & Berrios, G. E. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00015-8 · Cited by 394
Self-citationThe epidemiology of depersonalisation and derealisation
Sierra, M., David, A. S., & Hunter, E. C. M. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-004-0701-4 · Cited by 316
Self-citationEnadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
Walsh, S., Strain, E., Abreu, M., & Bigelow, G. (2001) · Psychopharmacology · doi:10.1007/s002130100788 · Cited by 258
Autonomic Response in Depersonalization Disorder
Sierra, M., Senior, C., Dalton, J., McDonough, M., Bond, A., Phillips, M. L., O'Dwyer, A. M., & David, A. S. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.9.833 · Cited by 225
Self-citationDepersonalization disorder: thinking without feeling.
Phillips, M. L., Medford, N., Senior, C., Bullmore, E. T., Suckling, J., Brammer, M. J., Andrew, C., Sierra, M., Williams, S. C. R., & David, A. S. (2001) · Psychiatry Research: Neuroimaging · doi:10.1016/s0925-4927(01)00119-6 · Cited by 215
Self-citationSIERRA, M., BAKER, D., MEDFORD, N., & DAVID, A. S. (2005) · Psychological Medicine · doi:10.1017/s0033291705005325 · Cited by 201
Self-citationFeeling unreal: a depersonalization disorder update of 117 cases
Simeon, D., Knutelska, M., Nelson, D., & Guralnik, O. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0903 · Cited by 181
Cited by
Dissociative disorders in DSM-5
Spiegel, D., Loewenstein, R. J., Lewis-Fernández, R., Sar, V., Simeon, D., Vermetten, E., Cardeña, E., & Dell, P. F. (2011) · Depression and Anxiety · doi:10.1002/da.20874 · Cited by 330
Millière, R. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00245 · Cited by 206
“There is also increasing evidence that glutamatergic dysfunction might be involved in the pathophysiology of depersonalization disorder (Chambers et al., 1999; Sierra, 2008).”
BackgroundDissociative disorders in DSM-5
Spiegel, D., Loewenstein, R. J., Lewis-Fernández, R., Sar, V., Simeon, D., Vermetten, E., Cardeña, E., & Dell, P. F. (2011) · Depression and Anxiety · doi:10.1002/da.20923 · Cited by 162
“In a review of the (limited) psychopharmacological treatments for DPD, Sierra[102] suggested that possible agents and neurobiological targets for DPD might include CB1 cannabinoid agonists, k opioid agonists, NMDA antagonists, and 5HT2C agonists.”
BackgroundPharmacotherapy for dissociative disorders: A systematic review
Sutar, R., & Sahu, S. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112529 · Cited by 42
Schulz, A., Matthey, J. H., Vögele, C., Schaan, V., Schächinger, H., Adler, J., Beutel, M. E., & Michal, M. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.03.051 · Cited by 36
Metadata
- Authors
- Sierra, M.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 8
- Issue
- 1
- Pages
- 19-26
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W1973197771
- Cited by
- 62
- References
- 23
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Depersonalization disorder: pharmacological approaches. https://app.cochat.ai/papers/10.1586/14737175.8.1.19
- The paper
- Sierra, M. (2008). Depersonalization disorder: pharmacological approaches. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.8.1.19
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.